Nkarta appoints manufacturing executive Angela Thedinga to its Board of Directors

Nkarta, Inc.

Appointed Angela Thedinga as independent Class I director effective March 28, 2022.
Received stock option for 32,000 shares vesting in three equal annual installments.
Will receive annual cash retainer of $40,000, pro-rated for Q1 2022.
Thedinga most recently CTO of Adverum Biotechnologies; previously at AveXis/Novartis Gene Therapies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Angela Thedinga

Director

NKTX · Nkarta, Inc.

Effective: 2022-03-28
Filed: March 29, 2022, 7:59 PM ET

On March 28, 2022, the Board of Directors (the "Board") of Nkarta, Inc. (the "Company"), on the recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from nine directors to ten directors and appointed Angela Thedinga to the Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Angela Thedinga was appointed as Director at Nkarta, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 28, 2022, the Board of Directors (the "Board") of Nkarta, Inc. (the "Company"), on the recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from nine directors to ten directors and appointed Angela Thedinga to the Board effective immediately.

View on SEC.gov

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-004854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.